Hoechstetter et al reported a prognostic model for patients with chronic lymphocytic leukemia (CLL) at Binet Stage A. The data was collected in the CLL1 trial. The authors are from the German CLL Study Group.
Patient selection: CLL with age <= 75 years, ECOG 0 or 1, Binet stage A
Parameters:
(1) age of the patient in years
(2) lymphocyte double time (LDT) in months
(3) serum beta-2 microglobulin in mg/L
(4) del(11q)
(5) del(17p)
(6) mutation status of IGHV (immunoglobulin heavy chain variable gene)
Parameter |
Finding |
Points |
age in years |
<= 60 years |
0 |
|
> 60 years |
1.5 |
LDT in months |
< 12 months |
1.5 |
0 |
>= 12 months |
0 |
serum beta-2 microglobulin |
<= 3.5 mg/L |
0 |
|
> 3.5 mg/L |
2.5 |
del(11q) |
absent |
0 |
|
present |
2.5 |
del(17p) |
absent |
0 |
|
present |
3.5 |
IGHV |
unmutated |
2.5 |
|
mutated |
0 |
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 14
Total Score |
Risk Group |
Cumulative Survival at 10 Years |
0 to 1.5 |
very low |
90% |
2 to 4 |
low |
73% |
4.5 to 6.5 |
high |
40% |
>= 7 |
very high |
18% |
Performance:
• The area under the ROC curve for time to first treatment (TTFT) was 0.72.
Specialty: Hematology Oncology